The patient then entered the ComPAKT phase Ib trial of olaparib and the AKT inhibitor capivasertib [44] and achieved RECIST stable disease with minor tumor regression to treatment lasting five months, before discontinuing trial for disease progression. Here, AKT1 is linked to neoplasm.